Kazuo Umezawa^*, Andrzej Breborowicz^†, Shamil Gantsev^‡

Oncology Research, Vol.28, No.5, pp. 541-550, 2020, DOI:10.3727/096504020X15929100013698

Abstract There have been great advances in the therapy of cancer and leukemia. However, there are still many neoplastic diseases that are difficult to treat. For example, it is often difficult to find effective therapies for aggressive cancer and leukemia. An NF- B inhibitor named dehydroxymethylepoxyquinomicin (DHMEQ) was discovered in 2000. This compound was designed based on the structure of epoxyquinomicin isolated from a microorganism. It was shown to be a specific inhibitor that directly binds to and inactivates NF- B components. Until now, DHMEQ has been used by many scientists in the world to suppress animal models of cancer and… More >

HAIYANG CHEN^1,2,#, JINGYAO SU^1,#, DANYANG CHEN^1,#, YUYE DU¹, RUILIN ZHENG¹, QINGLIN DENG², QIANQIAN DU³, BING ZHU^1,*, YINGHUA LI^1,*

BIOCELL, Vol.46, No.10, pp. 2267-2273, 2022, DOI:10.32604/biocell.2022.020218

Abstract At present, Hepatocarcinoma is one of the main causes of tumor related death all over the world. However, there are still many clinical restrictions on the treatment of liver cancer. Recently, L-Selenocystine has been shown to be a novel treatment for tumors, especially human glioma cells. But, the mechanism of L-Selenocystine against hepatocellular carcinoma remains unclear. Therefore, the main objective of this study was to investigate the effects of L-Selenocystine on HepG2 cell proliferation and activation of reactive oxygen species (ROS) mediated signaling pathway. L-Selenocystine can significantly inhibit HepG2 cell proliferation by activating caspase-3 and cleaving PARP to induce apoptosis.… More >